Global Acute Ischemic Stroke Therapeutics Market 2017-2021

  • ID: 4372298
  • Report
  • Region: Global
  • 84 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Bayer
  • Biogen
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • F. Hoffmann-La Roche
  • Pfizer
  • MORE
About Acute Ischemic Stroke Therapeutics

AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics market is expected to register a low single digit market growth during the forecast period. The marginal growth rate is attributed to the lack of approved drugs in this area, the presence of alternative therapies, extensive use of generics, and unmet needs for anticoagulant reversal agents.

The analysts forecast the global acute ischemic stroke therapeutics market to grow at a CAGR of 2.11% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global acute ischemic stroke therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs from various drug classes.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Acute Ischemic Stroke Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Bayer
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • Sanofi
Other prominent vendors
  • Biogen
  • Daiichi Sankyo
  • Pfizer
Market drivers
  • Increasing adoption of NOACs
  • For a full, detailed list, view the full report
Market challenges
  • Unmet needs for anticoagulant reversal agents
  • For a full, detailed list, view the full report
Market trends
  • TBI, a value-addition in AIS research
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer
  • Biogen
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • F. Hoffmann-La Roche
  • Pfizer
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
PART 05: Acute ischemic stroke (AIS): An overview
  • Ischemia
  • IHD
  • Stroke
  • AIS
PART 06: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 07: Pipeline landscape

PART 08: Market segmentation by drug-class
  • Thrombolytic therapeutics
  • Antihypertensive therapeutics
  • Antiplatelet therapeutics
  • Anticoagulants
  • Others
PART 09: Geographical segmentation
  • Market overview based on geography
  • AIS therapeutics market in Americas
  • AIS therapeutics market in EMEA
  • AIS therapeutics market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Market challenges
PART 12: Market trends
  • TBI, a value-addition in AIS research
  • Advent of genomic medicine
PART 13: Vendor landscape
  • Competitive scenario
  • Key news
PART 14: Key vendor analysis
  • Bayer
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • Sanofi
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Symptoms of AIS
Exhibit 02: Global AIS therapeutics market: Snapshot
Exhibit 03: Global AIS therapeutics market 2016-2021 ($ millions)
Exhibit 04: Mechanism of action of alteplase
Exhibit 05: Global AIS therapeutics market: Opportunity analysis
Exhibit 06: Five forces analysis
Exhibit 07: Pipeline snapshot
Exhibit 08: Key clinical trials
Exhibit 09: Global AIS therapeutics market segmentation by drug-class
Exhibit 10: Global AIS therapeutics market share by drug-class 2016
Exhibit 11: Global AIS thrombolytic therapeutics market 2016-2021 ($ millions)
Exhibit 12: Global AIS antihypertensive therapeutics market 2016-2021 ($ millions)
Exhibit 13: Global AIS antiplatelet therapeutics market 2016-2021 ($ millions)
Exhibit 14: Global AIS anticoagulant therapeutics market 2016-2021 ($ millions)
Exhibit 15: Global AIS therapeutics market share by geography 2016 and 2021
Exhibit 16: Global AIS therapeutics market by geography 2016-2021 ($ millions)
Exhibit 17: Global AIS therapeutics market by geography 2016-2021 (% share)
Exhibit 18: AIS therapeutics market scenario in different geographies
Exhibit 19: Market scenario in Americas
Exhibit 20: Stroke scenario in US: An overview
Exhibit 21: AIS therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 22: Market scenario in EMEA
Exhibit 23: AIS therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 24: Market scenario in APAC
Exhibit 25: AIS therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 26: Prevalence of stroke in US
Exhibit 27: ACTIVASE regional sales 2015 and 2016
Exhibit 28: Prevalence of obesity among US adults in 2015
Exhibit 29: Competitive structure analysis of global AIS therapeutics market 2016
Exhibit 30: Bayer: Key highlights
Exhibit 31: Bayer: Strength assessment
Exhibit 32: Bayer: Strategy assessment
Exhibit 33: Bayer: Opportunity assessment
Exhibit 34: Boehringer Ingelheim: Key highlights
Exhibit 35: Boehringer Ingelheim: Strength assessment
Exhibit 36: Boehringer Ingelheim: Strategy assessment
Exhibit 37: Boehringer Ingelheim: Opportunity assessment
Exhibit 38: F. Hoffmann-La Roche: Key highlights
Exhibit 39: F. Hoffmann-La Roche: Strength assessment
Exhibit 40: F. Hoffmann-La Roche: Strategy assessment
Exhibit 41: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 42: Sanofi: Key highlights
Exhibit 43: Sanofi: Strength assessment
Exhibit 44: Sanofi: Strategy assessment
Exhibit 45: Sanofi: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Bayer
  • Biogen
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • F. Hoffmann-La Roche
  • Pfizer
  • MORE
New Report Released: - Global Acute Ischemic Stroke Therapeutics Market 2017-2021

The author of the report recognizes the following companies as the key players in the global acute ischemic stroke therapeutics market: Bayer, Boehringer Ingelheim, F. Hoffmann-La Roche, and Sanofi.

Other Prominent Vendors in the market are: Biogen, Daiichi Sankyo, and Pfizer.

Commenting on the report, an analyst from the research team said: “One trend in the market is TBI, a value-addition in AIS research. AIS is a complex cardiac disorder which requires integration of various heterogeneous features originating from genotypic, phenotypic, and environmental sources. Modern approaches that can integrate and analyze these heterogeneous features are being developed to enhance the clinical guidelines for treating and preventing AIS and are called 'translational bioinformatics (TBI).”

According to the report, one driver in the market is increasing adoption of NOACs. The increasing adoption of NOACs among physicians is expected to drive the market growth. NOACs, such as dabigatran, rivaroxaban, and apixaban exert their pharmacological effects by either directly targeting thrombin or by inhibiting factor Xa, thereby preventing the formation of thrombus. They provide rapid onset of action and do not require regular coagulation monitoring. They also have better safety and efficacy profiles when compared with conventional therapies such as warfarin, which is associated with high risk of causing intracranial bleeding.

Further, the report states that one challenge in the market is unmet needs for anticoagulant reversal agents. Though anticoagulants play an important role in treating AIS, they are sometimes associated with side effects such as excessive bleeding. The side effects can be reversed using reversal agents, which are referred to as antidotes for anticoagulants. The antidotes available in the market include vitamin K, protamine, and prothrombin complex concentrates, which reverse the action of warfarin and heparin. Though NOACs show better safety and efficacy profiles, the acceptability of these drugs is low due to the unavailability of antidotes in the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Bayer
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • Sanofi
  • Biogen
  • Daiichi Sankyo
  • Pfizer
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll